{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-126425","form_type":"8-K","ticker":"RNTX","cik":"0001420565","company_name":"Rein Therapeutics, Inc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.340726+00:00","generated_at":"2026-06-03T02:36:33.585604+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M","bullets":["7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).","LTI-03 well-tolerated with no serious adverse events; solRAGE increased (p=0.1407), indicating type I epithelial cell health.","Cohort 1: 12 patients (9 active, 3 placebo), inhaled 2.5 mg BID; cohort 2 high-dose results expected Q3 2024.","Preliminary cash and cash equivalents ~$12.0M as of March 31, 2024, unaudited."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-126425","json":"https://secwatch.observer/filing/0001193125-24-126425.json","markdown":"https://secwatch.observer/filing/0001193125-24-126425.md","text":"https://secwatch.observer/filing/0001193125-24-126425.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524126425/0001193125-24-126425-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420565/000119312524126425/d65915d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:36:33.585604+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}